165 related articles for article (PubMed ID: 31571709)
1. "ADR PvPI" Android mobile app: Report adverse drug reaction at any time anywhere in India.
Prakash J; Joshi K; Malik D; Mishra O; Sachan A; Kumar B; Bhushan S; Kalaiselvan V; Singh GN
Indian J Pharmacol; 2019; 51(4):236-242. PubMed ID: 31571709
[TBL] [Abstract][Full Text] [Related]
2. Adverse event reporting tools and regulatory measures in India through outcome of Pharmacovigilance Programme of India.
Prakash J; Sachdeva R; Shrivastava TP; Jayachandran CV; Sahu A
Indian J Pharmacol; 2021; 53(2):143-152. PubMed ID: 34100398
[TBL] [Abstract][Full Text] [Related]
3. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
Tandon VR; Mahajan V; Khajuria V; Gillani Z
Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
[TBL] [Abstract][Full Text] [Related]
4. Pharmacovigilance in India: Present Scenario and Future Challenges.
Kalaiselvan V; Srivastava S; Singh A; Gupta SK
Drug Saf; 2019 Mar; 42(3):339-346. PubMed ID: 30269244
[TBL] [Abstract][Full Text] [Related]
5. Facilitators and Barriers to Uptake of the Med Safety Mobile App for Adverse Drug Reaction Reporting by Health Workers in Uganda: A Qualitative Study.
Kiguba R; Zakumumpa H; Ndagije HB; Mwebaza N; Ssenyonga R; Tregunno P; Harrison K; Pirmohamed M
Drug Saf; 2023 Jun; 46(6):565-574. PubMed ID: 37097426
[TBL] [Abstract][Full Text] [Related]
6. Development of Pharmacovigilance System in India and Paradigm of Pharmacovigilance Research: An Overview.
Singh P; Vaishnav Y; Verma S
Curr Drug Saf; 2023; 18(4):448-464. PubMed ID: 36200243
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic monoclonal antibodies and the need for targeted pharmacovigilance in India.
Kalaivani M; Singh A; Kalaiselvan V
MAbs; 2015; 7(1):276-80. PubMed ID: 25523367
[TBL] [Abstract][Full Text] [Related]
8. Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial.
Defer G; Le Caignec F; Fedrizzi S; Montastruc F; Chevanne D; Parienti JJ; Peyro-Saint-Paul L
Trials; 2018 Mar; 19(1):174. PubMed ID: 29523169
[TBL] [Abstract][Full Text] [Related]
9. Public-private partnership (3Ps) in ensuring safe use of medicines: An Indian experience.
Kalaiselvan V; Shukla S; Arora S; Shrivastava TP; Raghuvanshi RS
Front Public Health; 2022; 10():930696. PubMed ID: 36062131
[TBL] [Abstract][Full Text] [Related]
10. Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP
Montastruc F; Bagheri H; Lacroix I; Damase-Michel C; Chebane L; Rousseau V; Jouanjus E; Lapeyre-Mestre M; Durrieu G; Montastruc JL
Drug Saf; 2018 May; 41(5):511-514. PubMed ID: 29270770
[TBL] [Abstract][Full Text] [Related]
11. Cefixime-associated acute generalized exanthematous pustulosis: Rare cases in India.
Kumar V; Kalaiselvan V; Kumar AP; Saurabh A; Thota P; Sidhu S; Medhi B
Indian J Pharmacol; 2018; 50(4):204-207. PubMed ID: 30505057
[TBL] [Abstract][Full Text] [Related]
12. Drug safety alerts of pharmacovigilance programme of India: A scope for targeted spontaneous reporting in India.
Thota P; Thota A; Medhi B; Sidhu S; Kumar P; Selvan VK; Singh GN
Perspect Clin Res; 2018; 9(1):51-55. PubMed ID: 29430420
[TBL] [Abstract][Full Text] [Related]
13. Statistical Signal Process in R Language in the Pharmacovigilance Programme of India.
Kumar A; Ahuja J; Shrivastava TP; Kumar V; Kalaiselvan V
Ther Innov Regul Sci; 2018 May; 52(3):329-333. PubMed ID: 29714534
[TBL] [Abstract][Full Text] [Related]
14. Mobile apps for quick adverse drug reaction report: A scoping review.
Parracha ER; Advinha AM; Lopes MJ; Oliveira-Martins S
Pharmacoepidemiol Drug Saf; 2023 Jan; 32(1):19-27. PubMed ID: 36125022
[TBL] [Abstract][Full Text] [Related]
15. Awareness among tertiary care doctors about Pharmacovigilance Programme of India: Do endocrinologists differ from others?
Sharma PK; Singh S; Dhamija P
Indian J Endocrinol Metab; 2016; 20(3):343-7. PubMed ID: 27186551
[TBL] [Abstract][Full Text] [Related]
16. Pharmacovigilance Programme of India: Recent developments and future perspectives.
Kalaiselvan V; Thota P; Singh GN
Indian J Pharmacol; 2016; 48(6):624-628. PubMed ID: 28066097
[TBL] [Abstract][Full Text] [Related]
17. A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence.
Sharma PK; Misra AK; Gupta A; Singh S; Dhamija P; Pareek P
Indian J Pharmacol; 2018; 50(5):273-278. PubMed ID: 30636831
[TBL] [Abstract][Full Text] [Related]
18. Adverse drug reactions at adverse drug reaction monitoring center in Raipur: Analysis of spontaneous reports during 1 year.
Singh P; Agrawal M; Hishikar R; Joshi U; Maheshwari B; Halwai A
Indian J Pharmacol; 2017; 49(6):432-437. PubMed ID: 29674797
[TBL] [Abstract][Full Text] [Related]
19. Adverse Drug Reaction Reporting Using a Mobile Device Application by Persons with Multiple Sclerosis: A Cluster Randomized Controlled Trial.
Defer G; Fedrizzi S; Chevanne D; Montastruc F; Briant AR; Parienti JJ; Peyro-Saint-Paul L; ;
Drug Saf; 2021 Feb; 44(2):223-233. PubMed ID: 33048319
[TBL] [Abstract][Full Text] [Related]
20. How to promote adverse drug reaction reports using information systems - a systematic review and meta-analysis.
Ribeiro-Vaz I; Silva AM; Costa Santos C; Cruz-Correia R
BMC Med Inform Decis Mak; 2016 Mar; 16():27. PubMed ID: 26926375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
